(Q35621670)

9 August 2017

0 references

1 reference

title

Interferon-alpha for HBeAg-positive chronic hepatitis B. (English)

1 reference

9 August 2017

1 reference

Antonio Craxì

1

1 reference

PubMed ID

14708686

9 August 2017

Danilo Di Bona

series ordinal

2

1 reference

PubMed ID

14708686

9 August 2017

Calogero Cammà

series ordinal

3

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39 Suppl 1

1 reference

9 August 2017

S99-105

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

9 August 2017

1 reference

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Interferon for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Effect of interferon on hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Quantitative synthesis in systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Treatment of chronic hepatitis B with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Randomised controlled trial of recombinant human interferon -alpha A for chronic active hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Experience with interferon in chronic hepatitis B in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Effects of recombinant alpha interferon on chronic active hepatitis B: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Low dose alpha interferon treatment in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

The long-term course of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

An introduction to a Bayesian method for meta-analysis: The confidence profile method

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Does corticosteroid pretreatment enhance the effect of alfa interferon treatment in chronic hepatitis B?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900154-5

7 January 2021

10.1016/S0168-8278(03)00154-5

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14708686